Prometheus CEO and leadership

Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies. He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson. Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business.

Thierry Dervieux currently works as Chief Development Officer Diagnostics & Medical Director at Prometheus Biosciences, Inc. He previously worked at Exagen Inc. as Chief Scientific Officer and Medical Director.

Olivier Laurent currently works as Chief Technology Officer at Prometheus Biosciences, Inc. He previously worked at Intrepida Bio as Chief Scientific Officer.

Dr. Luo has served as Chief Medical Officer of Precision IBD, the predecessor of Prometheus Biosciences since August 2018. Prior to joining Prometheus Biosciences, Dr. Luo was Senior Vice President of Clinical Development for Gastroenterology at Progenity, and Vice President of Clinical Development at Ophthotech where she was responsible for the completion of two Phase 3 studies. Prior to Ophthotech, Dr. Luo was Executive Director at Bristol-Myers Squibb where she was responsible for Inflammatory Bowel Disease and led the Phase 3 program for Orencia (abatacept) and the Phase 2 program for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career she was a Medical Director at Abbott Laboratories where she led the regulatory filing of Humira for rheumatoid arthritis in Japan and developed the clinical trial protocols for Humira in ulcerative colitis. Dr. Luo received her Bachelor of Science in Biochemistry and Doctor of Medicine degrees from Northwestern University, followed by a residency in internal medicine at Loyola University, and a fellowship in drug development at Abbott Laboratories (Abbvie).

Cathy Kerzner is a Chief Executive Officer and President at Prometheus Biosciences and is based in United States. She works or has worked at Prometheus Laboratories Inc., A Nestlé Health Science Company.

Mr. Doughty joined Prometheus Biosciences as Senior Vice President of Corporate Development in February 2021. Chris joined Prometheus from Strata Oncology, a precision oncology company, where he served as Vice President of Strategy and Business Development and led the organization’s pharma business development efforts. Before pursuing opportunities focused in precision medicine, Chris began his career in strategy consulting, most recently serving as an Engagement Manager at McKinsey & Company and also having spent time at Kaufman Hall and Deloitte. Chris holds an MBA from the University of Michigan’s Ross School of Business and a B.S.E in Industrial Operations Engineering from the College of Engineering at the University of Michigan.

Dr. Marshall was appointed as the Chief Financial Officer in August 2020. Prior to joining Prometheus, Dr. Marshall served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Conatus Pharmaceuticals (Nasdaq: CNAT) since 2017. Prior to Conatus, he served as Chief Financial Officer and Head of Corporate Development at Torque Therapeutics (now Repertoire Immune Medicines), a Flagship Pioneering company. Dr. Marshall also served as Managing Director in Healthcare Investment Banking at GCA Savvian Advisors, Managing Director, Co-founder, and Chief Financial Officer at Montgomery, Marshall Healthcare Partners, and Managing Director of Healthcare Investment Banking at Montgomery & Co. He began his career in investment banking at JP Morgan. Dr. Marshall holds an MBA from the University of Chicago - Booth School of Business, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco and an A.B. in Biology from Washington University in St. Louis.

Mark Spring is a Senior VP:Finance/CFO at Prometheus Biosciences and Chief Financial Officer at Sotera Wireless Inc. He has worked as VP:Finance at BAXTER INTERNATIONAL INC; Senior VP/CFO at Horizon; and Chief Financial Officer at VERACYTE, INC.. Mark works or has worked as Executive at CORVEL CORP, Executive at DADE BEHRING INC, and Executive at Caremark International Ltd. He attended Monmouth University.

Mr. Stenhouse joined Prometheus Biosciences as the Chief Operating Officer in March 2021. Prior to joining Prometheus Biosciences, Mr. Stenhouse served as General Manager of the Screening Business Unit at Exact Sciences. Prior to Exact Sciences, he spent 27 years at AbbVie/Abbott serving most recently as Vice President, US Immunology, from October 2016 until March 2018. Prior to leading the US Immunology business, he served as Vice President and General Manager of the Gastroenterology franchise having spent 10 years working in Inflammatory Bowel Disease. Mr. Stenhouse currently serves as a member of the Board of Directors for Phathom Pharmaceuticals. He earned a BS in business from the College of Charleston.